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Summary
Objective: To evaluate effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate
(CS–G–M) on articular cartilage metabolism in dogs with cranial cruciate ligament (CCL) deficient and reconstructed knees, as reflected by
concentrations of synovial fluid 3B3, 7D4 and total sulfated glycosaminoglycan (GAG).
Methods: Sixteen adult dogs that underwent unilateral CCL transection were randomized into four groups. Thereafter, group I (N=3) had a
sham CCL reconstruction, group II (N=3) had CS–G–M and sham CCL reconstruction, group III (N=5) had CCL reconstruction, and group
IV (N=5) had CS–G–M and CCL reconstruction. Synovial fluid collected at 0, 1, 3 and 5 months was examined by ELISA for 3B3 and 7D4
epitope, and by DMMB assay for total GAG.
Results: Synovial fluid from CCL transected knees of CS–G–M treated dogs contained significantly elevated concentrations of 3B3
(P=0.029), 7D4 (P=0.036) and 7D4/GAG (P=0.007) in comparison to controls, in a cross-sectional analysis at 3 months. Furthermore, 7D4
and 7D4/GAG concentrations remained significantly elevated (P=0.012) in CCL transected knees of CS–G–M treated dogs over the 5 month
period. However, when epitope concentrations were expressed as a ratio of CCL-transected to contralateral non-operated knee, treatment
effect of CS–G–M was no longer significant. Reconstruction of the CCL had no significant effect on synovial fluid epitope.
Conclusions: Administration of CS–G–M was associated with altered concentrations of 3B3 and 7D4 epitope in synovial fluid, suggesting that
these compounds may act to modulate articular cartilage matrix metabolism in vivo. © 2001 OsteoArthritis Research Society International
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Of recent interest has been the treatment of osteoarthritis
(OA) with compounds such as chondroitin sulfate and
glucosamine.1–5 These oral products have been classified
as symptomatic, slow-acting disease-modifying OA
agents.3,6 In some European countries chondroitin sulfate
and glucosamine sulfate are registered as prescription
drugs, whereas in North America they are considered as
nutraceuticals and food supplements. Glucosamine is an
amino monosaccharide used in the synthesis of disaccha-
ride units of glycosaminoglycan (GAG).3 Both the large
aggregating proteoglycan (aggrecan) and the small, non-
aggregating proteoglycans (biglycan, decorin and fibro-
modulin) of articular cartilage are composed largely of GAG
chains. Keratan sulfate, and chondroitin 4- and 6-sulfates
are the main GAGs of articular cartilage.7 Also manganese14is a trace element and cofactor in the biosynthesis of
GAG.3 Ascorbate is required for collagen fibril formation
and cross-linking, but it is non-essential to dogs because
of their capacity for endogenous hepatic synthesis of
ascorbate.
The rationale for using nutraceuticals is that provision of
precursors of cartilage matrix in excess quantities may
favor matrix synthesis and repair of articular cartilage. A
mixture containing chondroitin sulfate, glucosamine hydro-
chloride and manganese ascorbate was chondro-
protective in a rabbit knee instability model.8 In addition to
potential biosynthetic effects, glucosamine may have
cyclooxygenase-independent, anti-inflammatory proper-
ties.9,10 Also, IL-1 or retinoic acid-induced cleavage of
aggrecan by aggrecanase in vitro was inhibited by glucos-
amine.11 Although there are several reports describing
clinical trials of oral chondroitin sulfate alone, or in com-
bination with glucosamine, that document sympto-
matic improvement in humans and animals with OA, little
is known about the mechanisms of action of these
compounds.2,4,5,12,13
Early in the process of OA there is increased synthesis
and turnover of matrix proteoglycans and collagens by
chondrocytes.14–19 One feature of this altered matrix syn-
thesis is that some of the newly formed chondroitin sulfatesReceived 3 December 1999; accepted 18 April 2000.
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patterns and structure, exposing unique epitopes that are
detectable by immuno-assay using monoclonal antibodies
such as 3B3 and 7D4.20–23 These antibodies have been
used to demonstrate modulation of chondroitin sulfate
structure in both articular cartilage and synovial fluid in OA
secondary to knee injury in man and animal models.24–26
They are also potentially useful in monitoring disease
progression and response to therapy.27
The canine cranial cruciate ligament (CCL—equivalent
to anterior cruciate ligament in man) transection model of
induced OA was used in our study because it is well
characterized and clinically relevant, and it permits longi-
tudinal studies of synovial fluid composition.14–19,28 How-
ever, a shortcoming of this model is that chronic joint
instability contributes to ongoing deterioration in the bio-
chemical and mechanical properties of articular cartilage,
so potentially some subtle benefits of oral chondromodulat-
ing or chondroprotective agents may be obscured or over-
whelmed.29 Thus we felt that it was important to examine
also the effects of these agents in CCL transected joints
that had been reconstructed. Therefore, the purpose of our
study was to use a canine model of OA induced by CCL
transection to examine the effects of orally-administered
chondroitin sulfate, glucosamine hydrochloride and manga-
nese ascorbate, both with and without CCL reconstruction.
We hypothesized that these orally administered com-
pounds would modulate cartilage matrix synthesis in joints
with OA, and that this effect would be reflected by altera-
tions in levels of chondroitin sulfate 3B3 and 7D4 epitope
and GAG in synovial fluid.SYNOVIAL FLUID
Synovial fluid was collected from left and right stifle joints
by direct arthrocentesis at time zero and 1 month while
dogs were anaesthetized for surgery. Further synovial fluid
samples were collected at 3 months while dogs were
sedated, and at 5 months immediately after euthanasia.
Synovial fluid was centrifuged at 12000 g for 30 min at 4°C,Table I
Treatment groups (chondroitin sulfate-glucosamine hydrochloride-manganese ascorbate and cranial cruciate ligament reconstruction) of
dogs with unilateral osteoarthritis induced by cranial cruciate ligament transection at time zero
Group N Treatment
I Control 3 Sham arthrotomy at 4 weeks
II CS–G–M 3 Daily oral CS–G–M commencing day one and sham arthrotomy at 4 weeks
III R–CCL 5 Arthrotomy and CCL reconstruction at 4 weeks
IV CS–G–M+R–CCL 5 Daily oral CS–G–M commencing day one, and arthrotomy and CCL reconstruction at 4 weeks
CS–G–M=chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate.
R–CCL=cranial cruciate ligament reconstruction.Materials and methods
ANIMALS AND OSTEOARTHRITIS MODEL
Sixteen adult pure bred hounds of either sex, weighing
23–32 kg and with no clinical or radiographic evidence of
joint disease were used for the study, which was conducted
according to AALAC guidelines. The right or left hind limb
was randomly selected and the CCL was surgically
transected through a medial arthrotomy in all dogs.30 The
contralateral limb served as a non-operated, negative
control. Dogs were randomly assigned to one of four
experimental groups (Table I).CHONDROITIN SULFATE, GLUCOSAMINE HYDROCHLORIDE AND
MANGANESE ASCORBATE ADMINISTRATION
Gelatin capsules, each containing a commercial
formulation of 200 mg low molecular weight chondroitin
sulfate (95% sodium chondroitin sulfate and 5% mixedGAG; TRH122Y), 250 mg glucosamine hydrochloride
(FCHG49Y) and 5 mg manganese ascorbate (CS–G–M;
Cosequin®, Nutramax Laboratories® Inc, Edgewood, MD)
were used for the study. The sodium chondroitin sulfate
was derived from bovine trachea and the glucosamine was
from chitin of crustacean shells. Commencing one day after
CCL transection, each dog in Groups II and IV (Table I)
was dosed orally with three capsules every 12 hours, for
30 days. Thereafter, each of these dogs was given two
capsules every 12 hours until the time of euthanasia at
5 months.CRANIAL CRUCIATE LIGAMENT RECONSTRUCTION
Four weeks after CCL transection, six dogs (Groups I
and II) underwent a sham arthrotomy on the CCL deficient
stifle, to serve as a non-reconstructed control. Ten dogs
(Groups III and IV) had CCL reconstruction by isometric
placement of an intracapsular graft, as previously
described.31 Briefly, an intracapsular graft was fashioned
from distal fascia lata and patella tendon. Distally, the graft
and its insertion onto the tibial plateau were freed with an
osteotome. A tibial tunnel was created to enter the joint at
the most caudal point of insertion of the normal CCL. A
generous notchoplasty was made to protect the graft and
permit adequate visualization of the caudo-proximal point
for entry of a femoral tunnel into the joint. The femoral
tunnel was made and the graft placed through each tunnel.
The limb was positioned at an angle of 135° and approxi-
mately 1.4 kg of tension was placed on the graft that was
then sutured to the lateral femoro-fabellar ligament.POST-SURGICAL MANAGEMENT
For analgesia, all dogs were given buprenorphine
(0.03 mg/kg IM) immediately prior to surgery and again
during recovery, and the limb was maintained in a soft
padded bandage for 3–4 days. Dogs were housed in
2.5×1.2 m runs and exercised by leash walking for
15 minutes every third day until the time of euthanasia and
necropsy 5 months post-operatively. Morphologic data on
joints were reported previously.32
16 K. A. Johnson et al.: CS, glucosamine HCL and manganese mixture in OAand the supernatant stored at −80°C until assayed. Label-
ling of tubes was in code and investigators performing
synovial fluid assays were blinded to treatment groups.Results
CROSS-SECTIONAL ANALYSES
One month
Results of the cross-sectional analysis at 1 month com-
paring data only from CCL-transected knees are shown in
Table II. There were no significant differences between the
CS–G–M and non-CS–G–M groups. There was a near-
significant difference in 3B3 levels (P=0.095) between
CS–G–M and non-CS–G–M groups; the latter group had a
lower mean value. We calculated that 27 dogs per groupTable II
Cross-sectional analysis of effect of chondroitin sulfate, glucos-
amine hydrochloride and manganese ascorbate on synovial fluid in
operated knee joints one month after cranial cruciate ligament
transection
CS–G–M*
N=8
Non-CS–G–M*
(N=8)
P-value†
3B3‡ 123.7 86.7 0.095
(ng/ml) (79.8, 191.8) (73.3, 102.6)
7D4‡ 98.5 68.9 0.116
(ug/ml) (65.7, 147.7) (50.9, 93.3)
GAG‡ 82.2 74.1 0.552
(ug/ml) (58.9, 114.6) (59.0, 93.0)
3B3/GAG§ 1.82 1.22
(ng/ug) (0.72, 2.92) (0.91, 1.53) 0.249
7D4/GAG§ 1.23 0.98
(ug/ug) (0.97, 1.50) (0.73, 1.23) 0.119
*Chondroitin sulfate, glucosamine hydrochloride and manga-
nese ascorbate.
†Resulting from a two sample t-test.
‡Figures are geometric means and 95% confidence intervals
within groups.
§Figures are arithmetic means and 95% confidence intervals
within groups.SULFATED GLYCOSAMINOGLYCAN CONTENT OF SYNOVIAL FLUID
Aliquots of synovial fluid supernatant were digested in
buffered papain solution (20 units/mg protein, Sigma
Chemical Co., St Louis, MO, U.S.A.) as described pre-
viously.24 After inactivation of the enzyme by addition of
iodoacetic acid, supernatants were treated with hyaluroni-
dase (streptomyces hyalurolyticus, 2000 TRU/mg; Seika-
gaka Corp., Japan), and then sulfated GAG levels were
measured using a dye-binding assay.24,33,34 Shark chon-
droitin sulfate standards (Sigma Chemical Co., St Louis,
MO, U.S.A.) in the range of 0–40 l/ml were prepared. After
addition of 1,9 dimethylmethylene blue (Molecular Probes,
Inc., U.S.A.) solution33,34 to each plate well (Immulon 2,
Dynatech Lab, Inc., U.S.A.) containing sample or standard,
shifts in absorbency were detected immediately at 530 nm
on a plate reader (EL 312e Bio-Kinetics Microplate Reader,
Bio-Tek Instruments, VT, U.S.A.).3B3 ASSAY
A competitive equilibrium ELISA based on a previously
described method24 was used with the following variations
to quantify 3B3 epitope levels in synovial fluid. Synovial
fluid samples were diluted 1:10 in saline. Standards of
porcine aggrecan core protein (a generous gift from
Professor Michael T. Bayliss, London) in the range 1.95–
500 ng/ml were prepared, and monoclonal antibody 3B3
(Seikagaka Co., Tokyo, Japan) at dilution of 1:1600 (final
dilution 1:3200) was used. Blank (Tris buffer only) and
reference wells (antibody only, no competing antigen) were
also included in each plate. Second antibody, anti-mouse
IgM peroxidase conjugate (Sigma Chemical Co., St Louis,
MO, U.S.A.) was diluted 1:1000. Color reaction was read
60 min after addition of peroxidase substrate (ABTS,
Sigma) on a plate reader at 405 nm. The 3B3 levels were
calculated in equivalent weight of the antigen standard,
using the absorbency compared to reference wells (no
antigen), and by reading this value against the standard
curve of percentage of inhibition against the standard
antigen concentration.247D4 ASSAY
This assay was similar to the 3B3 ELISA, with the
following exceptions. Monoclonal antibody 7D4 was a
generous gift of Professor Bruce Caterson (University of
Cardiff). Antigen used for coating microplates and
preparation of standards was bovine laryngeal cartilage
proteoglycan generously provided by Professor Michael T.
Bayliss. Plates were coated at 1 g/ml and standards
ranged from 0.0156 to 4 g/ml of sulfated GAG, as deter-
mined by the GAG dye-binding assay. Synovial fluid
samples were diluted 1:20 in saline. The 7D4 was applied
at a dilution of 1:25 000 (final dilution 1:50 000). Second
antibody IgM was diluted 1:1000. Plates were read at 2 h
after addition of peroxidase substrate on the plate reader.DATA ANALYSIS
Due to heterogeneity in variance of the data obtained
from synovial fluid analyses, raw values were log (natural)transformed prior to performing statistical analyses on 3B3,
7D4 and GAG data, but not the 3B3/GAG or 7D4/GAG
ratios. Where appropriate, data have been presented in our
results after back transformation to geometric means.
Cross-sectional analyses were performed to compare
mean synovial fluid levels of 3B3, 7D4, GAG, 3B3/GAG
and 7D4/GAG between CCL-transected knees. Also,
cross-sectional analyses were performed to compare ratios
of synovial fluid levels of 3B3, 7D4 and GAG in CCL-
transected knee over contralateral nonoperated knee. A
cross-sectional analysis of 1 month data compared the
CS–G–M groups (II and IV) to the non-CS–G–M groups
(I and III). Cross-sectional analyses of 3 month data used a
two-way analysis of variance with CS–G–M treatment as
one factor and CCL reconstruction as the second. A two
sample t-test was used to test for a difference in mean
values.
A longitudinal analysis was performed using dogs for
which data at all four time points were available. A repeated
measures analysis of variance was used to test for any
between-group effects, time effects and group-time inter-
actions. The Greenhouse–Geisser adjustment was applied
to time effect tests. Missing data were assumed to be
missing completely at random and no imputations for such
missing values were made. Statistical significance was set
at the 5% level. No adjustments were made for multiple
hypothesis testing.
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significant (P<0.05) at a power of 90%.35
Results of the 1 month cross-sectional analyses compar-
ing mean ratios of values for CCL-transected to contra-
lateral non-operated knees are presented in Table III. There
were no significant differences in 3B3, 7D4 and GAG levels
between the CS–G–M and non-CS–G–M groups. The 95%
confidence intervals for the 3B3 data included unity and
therefore differences between operated and non-operated
knees were not significant. However, means and 95%
confidence intervals for 7D4 and GAG data were above
unity, indicating significantly higher 7D4 and GAG levels
in synovial fluids of CCL-transected knees compared to
non-operated knees, irrespective of CS–G–M treatment.Three months
At 3 months, levels of 3B3 (P=0.029), 7D4 (P=0.036)
and 7D4/GAG ratio (P=0.007) in synovial fluid in the
CCL-transected knees were significantly elevated in
CS–G–M treated dogs, compared to non-CS–G–M treated
dogs (Table IV; Fig. 1). Cranial cruciate ligament recon-
struction had no significant effect on concentrations of 3B3,
7D4 or GAG in these joints (Table IV). In the analysis of
ratios, means and 95% confidence intervals for 3B3, 7D4
and GAG excluded unity, with the one exception (3B3,
non-CS–G–M), indicating significantly higher levels in the
CCL-transected knee than the non-operated contralateral
knee, but without any significant treatment effect due to
CS–G–M or CCL reconstruction (Table V).Table III
Cross-sectional analysis of effect of chondroitin sulfate, glucos-
amine hydrochloride and manganese ascorbate on synovial fluid 1
month after cranial cruciate ligament transection: ratio of operated
knee to contralateral non-operated knee*
CS–G–M†
(N=8)
Non-CS–G–M†
(N=8)
P-value‡
3B3 0.998 0.940 0.163
(ng/ml) (0.946, 1.050) (0.864, 1.016)
7D4§ 1.637 1.487 0.367
(ug/ml) (1.348, 1.926) (1.242, 1.732)
GAG\ 1.289 1.289 0.999
(ug/ml) (1.177, 1.400) (1.108, 1.469)
*Figures are arithmetic means and 95% confidence intervals
within groups.
†Chondroitin sulfate, glucosamine hydrochloride and manga-
nese ascorbate.
‡Resulting from a two sample t-test.
§Data available for only seven dogs in non-CS–G–M group
(15 dogs in total).
\Data available for only five dogs in non-CS–G–M group
(13 dogs in total).Table IV
Cross-sectional analysis of effect of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate, and cranial cruciate ligament
reconstruction on synovial fluid in operated knee joints 3 months after cranial cruciate ligament transection
CS–G–M
(N=8)
Non CS–G–M
(N=8)
P-value* Reconstruction
(N=10)
No
reconstruction
(N=6)
P-value†
3B3‡§ 248.4 181.1 204.9 229.5
(ng/ml) (207.5, 297.5) (138.6, 236.5) 0.029 (157.8, 266.2) (183.2, 287.4) 0.412
7D4§ 71.5 47.8 52.1 70.9
(ug/ml) (48.7, 105.0) (38.8, 59.0) 0.036 (42.3, 64.3) (40.6, 70.9) 0.108
GAG§\ 53.9 54.3 50.6 59.8
(ug/ml) (35.5, 81.7) (41.1, 71.7) 0.998 (38.3, 66.7) (36.4, 98.5)
3B3/GAG‡¶ 5.26 3.57 4.63 4.23
(ng/ug) (2.83, 7.69) (2.36, 4.78) 0.202 (2.54, 6.72) (2.13, 6.34) 0.758
7D4/GAG\¶ 1.34 0.92 1.10 1.21
(ug/ug) (1.21, 1.46) (0.62, 1.23) 0.007 (0.82, 1.38) (0.95, 1.47) 0.425
*Resulting from a two-way ANOVA: testing for CS–G–M effect.
†Resulting from a two-way ANOVA: testing for CCL reconstruction effect.
‡Data available for only nine dogs in reconstruction group, seven in non-CS–G–M group (15 dogs in total).
§Figures are geometric means and 95% confidence intervals within groups.
\Data available for only nine dogs in reconstruction group, seven in non-CS–G–M group (15 dogs in total).
¶Figures are arithmetic means and 95% confidence intervals within groups.LONGITUDINAL ANALYSIS
Results of analyses comparing mean synovial fluid
levels from the CCL-transected knees (Fig. 1), and also
mean ratios of synovial fluid levels in CCL-transected knee
over contralateral non-operated knee are presented in
Table VI. There was a significant overall difference in 7D4
and 7D4/GAG levels between CS–G–M and non-CS–G–M
groups (P=0.012); the latter group had a lower mean value.
There were no significant effects with respect to CCL
reconstruction. There was a significant time effect for all
3B3, 7D4 and GAG absolute values and ratios, indicating
that CCL transection resulted in a significant change in
these variables compared to time zero, and also compared
to the contralateral non-operated knee. As there were
no significant time×CS–G–M or time×CCL reconstruction
interactions there was not any evidence of a difference in
time effect between groups (Table VI).Discussion
Clinical trials have suggested that nutraceuticals or
slow-acting disease-modifying OA agents contribute to
symptomatic relief of pain in humans and animals with
18 K. A. Johnson et al.: CS, glucosamine HCL and manganese mixture in OAOA,2,4,12,13,36 but the mechanisms by which these com-
pounds act are largely unknown. Evidence derived from in
vitro studies suggest that alterations in proteoglycan bio-
synthesis, as well as anti-inflammatory, anti-catabolic and
chondroprotective actions may contribute to the beneficial
effects observed clinically.5,8,10,11,37,38 Our study of a
canine model of surgically induced OA is among the first to
provide in vivo evidence that chronic oral administration of
CS–G–M resulted in modulation of articular cartilage
metabolism that was reflected in synovial fluid 3B3 and 7D4
epitope concentrations. These findings are in accord with
morphologic observations that Mankin scores and joint
capsule thickening were less in CS–G–M treated dogs.32
The administration of CS–G–M over the course of 5
months resulted in significant alterations in 7D4 and 7D4/
GAG concentrations in synovial fluid of CCL transected
knees. Also, in cross-sectional analysis at three months,
levels of 3B3, 7D4 and 7D4/GAG ratio were significantly
elevated in the CCL-transected knees in CS–G–M treated
dogs, compared to non-CS–G–M treated dogs. However,
when synovial fluid variables in the CCL-transected knees
were expressed as a ratio to the contralateral nonoperated
knee, there were no significant treatment effects due to
CS–G–M, suggesting that the effects of these compounds
on synovial fluid composition were systemic and not local-
ized to osteoarthritic joints. Pharmacokinetic studies in
dogs and other animals have shown that both glucosamine
and chondroitin sulfate are absorbed from the gastro-
intestinal tract after oral administration,39,40 and radio-
labeled chondroitin sulfate was incorporated into normal
articular cartilage.7 Our results suggest that the effects of
these compounds in vivo were to modulate GAG struc-
ture in both normal and osteoarthritic joints, such that an
absolute increase in 3B3 and 7D4 epitope antigenic sites
resulted. Their effects were not simply due to increased
GAG synthesis by chondrocytes as had been suggested
previously,37 because there were no significant differences
between groups (CS–G–M vs non-CS–G–M) in total GAG
content of synovial fluid.
It has been proposed that 3B3 and 7D4 are ‘anabolic’
markers of cartilage turnover, and result from attempts by
chondrocytes to repair or remodel damaged cartilage in
OA, but they are not definitive ‘markers’ of OA.27 Mono-
clonal antibody 3B3 recognizes an epitope on chondroitin
sulfate chains that have a non-reducing termination of
GlcA1,3GalNAc6S-.41 The proportion of such terminal
disaccharides, at about 9%, remains constant throughoutTable V
Cross-sectional analysis of effect of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate, and cranial cruciate ligament
reconstruction on synovial fluid 3 months after cranial cruciate ligament transection: ratio of operated to contralateral non-operated knee*
CS–G–M
(N=8)
Non-CS–G–M
(N=8)
P-value† Reconstruction
(N=10)
No reconstruction
(N=6)
P-value‡
3B3§ 1.12 1.09 1.07 1.16
(ng/ml) (1.03, 1.23) (0.97, 1.20) 0.397 (1.00, 1.15) (1.02, 1.30) 0.165
7D4\ 1.52 1.53 1.48 1.58
(ug/ml) (1.36, 1.69) (1.35, 1.71) 0.935 (1.35, 1.62) (1.37, 1.79) 0.360
GAG¶ 1.19 1.10 1.13 1.19
(ug/ml) (1.08, 1.30) (1.02, 1.18) 0.097 (1.09, 1.17) (1.02, 1.36) 0.370
*Figures are arithmetic means and 95% confidence intervals within groups.
†Resulting from a two-way ANOVA allowing for CS–G–M treatment.
‡Resulting from a two-way ANOVA allowing for CCL reconstruction.
§Data available for only nine dogs in CCL reconstruction group (15 in total).
\Data available for only eight dogs in CCL reconstruction group (14 in total).
¶Data available for only six dogs in CCL reconstruction group (12 in total).60
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Fig. 1. Synovial fluid concentrations of 3B3 (A) and 7D4 (B) in
cranial cruciate ligament transected knees of dogs given an oral
mixture of chondroitin sulfate, glucosamine hydrochloride and
manganese ascorbate (CS–G–M). (Data shown are geometric
means for dogs with complete data sets at all four time points.)
*Differences between groups in 3B3 and 7D4, by cross-sectional
analysis at 3 months are significant (P<0.05). †Differences
between groups by longitudinal-analysis over five months are
significant (P=0.012).
(A)
(B)
Osteoarthritis and Cartilage Vol. 9 No. 1 19life but the immunoreactivity of the proteoglycans varies
with stage of development, maturity and pathology of
connective tissues, because chain length and presentation
are critical factors for recognition of chain terminations by
monoclonal antibody 3B3.41 Proteoglycans isolated from
osteoarthritic cartilage and synovial fluid showed increased
immunoreactivity to 3B3,24,27,42 which may in part have
been due to alterations in the sulfation and length of chains
ending with the disaccharide containing the 3B3 epitope.43
The epitope for monoclonal antibody 7D4 is less well
characterized, but 7D4 appears to recognize subtle combi-
nations of sulfated and non-sulfated disaccharide isomers
within the native chondroitin sulfate chain.27 Expression of
the 7D4 epitope is also more prevalent in proteoglycans
extracted from osteoarthritic cartilage and synovial
fluid.27,44
In our model, transection of the CCL for the purpose of
induction of secondary OA was responsible for much
greater alterations in synovial fluid levels of 3B3, 7D4 and
GAG than CS–G–M, both over time and as compared to
the contralateral non-operated knee. The one exception
occurred at 1 month after CCL transection, when 3B3 in the
operated knee was not significantly different from the
contralateral non-operated knee, but by 3 months levels of
3B3 in the CCL-transected knee were significantly greater.
This suggests that there is a lag period of about 4 weeks
after induction of the process of OA in this model before
GAG containing the 3B3 epitope begins to be released
from articular cartilage into synovial fluid in increased
quantities, which perhaps relates to delayed upregulation
of aggrecan mRNA expression in articular cartilage.45 This
delay was not detected in a previous study of the same
model in which synovial fluid 3B3 levels were only
measured at 6 and 12 weeks after CCL transection.46
Another important difference between our study and the
previous one46 was that we collected synovial fluid by
direct aspiration arthrocentesis and performed ELISA on
known dilutions of synovial fluid, whereas others have used
saline lavage of joints to facilitate collection of synovial
fluid,46 so final concentration of epitope in synovial fluid
could not be accurately determined. We have observed
that saline dilution of synovial fluid causes non-linear and
unpredictable increases in measured levels of 3B3 epitope
by ELISA, perhaps because there is unmasking or
increased presentation of antigenic sites (Johnson KA,
unpublished data).
By contrast to the observed changes in 3B3, we found
that CCL transection induced a significant elevation in both
7D4 and 7D4/GAG at 1 month that was sustained over thefollowing 4 months. Total GAG content of synovial fluid in
CCL-transected joints also increased over time, and this
change corresponds with the findings of other studies of
canine knees with OA secondary to naturally occurring CCL
rupture in which GAG content was elevated in early stages,
but in chronic disease declined and was negatively corre-
lated to radiographic scores.47,48 This is also consistent
with findings in chronic knee OA in humans.49,50 Cranial
cruciate ligament reconstruction had no significant effect on
synovial fluid variables, suggesting that attempts to elimi-
nate anterior drawer motion in the knee with an anatomical
autologous reconstruction has no significant effect on the
alterations in articular cartilage metabolism that are initi-
ated by surgically induced joint instability. This is consistent
with the observations that reconstruction of the anterior
cruciate ligament in humans does not prevent the late
development of secondary OA, in spite of the improvement
in function and joint stability.51,52
It is important to appreciate that our study focused on
changes in synovial fluid, as reflections of structural
changes in articular cartilage. Advantages of longitudinal
studies of synovial fluid markers over magnetic resonance
imaging or arthroscopy are economics and non-
invasiveness. However, it is assumed that most GAG in
synovial fluid is derived from the articular cartilage and not
the meniscal cartilages or synovial membrane. The present
study did not evaluate lameness or joint function and
further study is needed to elucidate mechanisms by which
CS–G–M produces symptomatic alleviation of pain in OA.
However, our study has provided evidence from an in vivo
model of OA that chronic oral administration of CS–G–M
resulted in altered synovial fluid 3B3 and 7D4 epitope
concentrations which may be a reflection of a modulation in
articular cartilage metabolism. Until our understanding of
the significance of these epitopes is more complete, it may
be premature to try to say whether the observed effects
of CS–G–M were beneficial to osteoarthritic articular
cartilage.Table VI
Longitudinal analysis of synovial fluid variables in knees with CCL transection alone, and as a ratio of operated
to contralateral non-operated knee: effects of chondroitin sulfate-glucosamine hydrochloride-manganese
ascorbate, repair and time*
Effect 3B3
(N=12)
7D4
(N=12)
GAG
(N=11)
3B3/GAG
(N=10)
7D4/GAG
(N=10)
3B3
O:NO ratio†
(N=9)
7D4
O:NO ratio
(N=8)
CS–G–M 0.181 0.012 0.451 0.191 0.012 0.249 0.688
CCL Reconstruction 0.357 0.568 0.250 0.717 0.651 0.273 0.756
Time‡ 0.003 <0.001 <0.001 0.006 0.002 0.035 0.014
Time×CS–G–M‡ 0.118 0.895 0.521 0.077 0.166 0.656 0.980
Time×Reconstruction‡ 0.874 0.166 0.807 0.702 0.400 0.471 0.560
*Figures are P-values resulting from repeated measures ANOVA.
†O:NO=operated knee to nonoperated knee.
‡Adjustment made using the Greenhouse–Geisser Epsilon.Acknowledgments
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